Skip to content

A single center, prospective, observational cohort study of mesangial score in predicting the clinical efficacy of laparoscopic D2 lymphadenetomy plus complete mesogastrium excision (D2+CME) in locally advanced gastric cancer

A single center, prospective, observational cohort study of mesangial score in predicting the clinical efficacy of laparoscopic D2 lymphadenetomy plus complete mesogastrium excision (D2+CME) in locally advanced gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058556
Enrollment
Unknown
Registered
2022-04-10
Start date
2022-01-01
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced gastric cancer

Interventions

case series:None

Sponsors

Putian First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18 years < age < 80 years; 2. The primary gastric lesions were confirmed by endoscopic biopsy and postoperative pathology as gastric adenocarcinoma (papillary adenocarcinoma PAP, tubular adenocarcinoma TUB, mucinous adenocarcinoma MUC, sig-ring cell carcinoma, and poorly differentiated adenocarcinoma POR); 3. The preoperative clinical staging was locally advanced gastric cancer (cT2-4a, N-/+, M0, according to AJCC-8th TNM tumor staging); 4. Preoperative examination showed no distant metastasis; 5. Preoperative ECOG physical status score 0/1; 6. Preoperative ASA score I-III; 7. Informed consent of patients.

Exclusion criteria

Exclusion criteria: 1. History of gastric surgery (including ESD/EMR for gastric cancer); 2. Neoadjuvant therapy has been implemented; 3. Concurrent surgical treatment for other diseases is required; 4. Gastric cancer is complicated (bleeding, perforation, obstruction) and requires emergency surgery; 5. Other patients with serious uncontrolled cardiopulmonary insufficiency, bone marrow hematopoietic function, coagulation dysfunction, liver function, renal insufficiency, cardiovascular and cerebrovascular diseases and other corresponding contraindications; 6. Pregnant or lactating patients; 7. Can't cooperate because of mental illness.

Design outcomes

Primary

MeasureTime frame
3 and 5-year survival rate;Positive rate of cancer cells from intraperitoneal;Blood loss during operation;The number of lymph node dissection;Intestinal recovery exhaust time;Operation time;Tumor deposit;Time of starting fluid diet;Complications;

Countries

China

Contacts

Public ContactLi Zhixiong

Putian First Hospital

lzx200003300@126.com+86 13808591898

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026